Safety, immunologic and clinical activity of Durvalumab in combination with Olaparib or Cediranib in advanced leiomyosarcoma: Results of the DAPPER clinical trial

Non-inflamed (cold) tumors such as leiomyosarcoma (LMS) do not benefit from immune checkpoint blockade (ICB) monotherapy. Combining ICB with angiogenesis-, or poly-ADP ribose polymerase (PARP) inhibitors may increase tumor immunogenicity by altering the immune cell composition of the tumor microenvi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2023-10, Vol.29 (20), p.4128-4138
Hauptverfasser:	Salawu, Abdulazeez, Wang, Ben X, Han, Ming, Geady, Caryn, Heirali, Alya, Berman, Hal K, Pfister, Thomas D, Hernando-Calvo, Alberto, Al-Ezzi, Esmail Mutahar, Stayner, Lee-Anne, Gupta, Abha A, Ayodele, Olubukola, Lam, Bernard, Hansen, Aaron R, Spreafico, Anna, Bedard, Philippe L, Butler, Marcus O, Avery, Lisa, Coburn, Bryan, Haibe-Kains, Benjamin, Siu, Lillian L, Abdul Razak, Albiruni R
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!